Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50

Capricor Therapeutics Inc (NASDAQ:CAPR) has earned an average recommendation of “Buy” from the six research firms that are covering the company, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $34.50.

CAPR has been the subject of a number of analyst reports. Cantor Fitzgerald upped their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Tuesday, March 4th.

Capricor Therapeutics Stock Down 2.1 %

NASDAQ CAPR opened at $12.79 on Tuesday. The stock has a market cap of $581.56 million, a PE ratio of -12.07 and a beta of 4.10. Capricor Therapeutics has a fifty-two week low of $3.52 and a fifty-two week high of $23.40. The business has a 50 day moving average price of $14.27 and a two-hundred day moving average price of $14.22.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Summit Investment Advisors Inc. raised its position in shares of Capricor Therapeutics by 54.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 1,345 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Capricor Therapeutics by 22.4% during the 4th quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 2,361 shares in the last quarter. Invesco Ltd. raised its position in shares of Capricor Therapeutics by 20.5% during the 4th quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 2,500 shares in the last quarter. Russell Investments Group Ltd. grew its stake in Capricor Therapeutics by 172.8% during the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after buying an additional 2,947 shares during the last quarter. Finally, Corebridge Financial Inc. grew its stake in Capricor Therapeutics by 32.2% during the 4th quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company’s stock worth $251,000 after buying an additional 4,434 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.